Topics

FDA Approves Aimmune's (AIMT) Palforzia, Stock Up 17% In After-Hours

20:03 EST 31 Jan 2020 | RTTNews

The FDA has approved Aimmune Therapeutics Inc.'s (AIMT) Palforzia for the treatment of peanut allergy in patients aged 4 through 17 years.

Original Article: FDA Approves Aimmune's (AIMT) Palforzia, Stock Up 17% In After-Hours

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Aimmune's (AIMT) Palforzia, Stock Up 17% In After-Hours"

Quick Search

Relevant Topic

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...